News | January 22, 2024
Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
Automated parallel capillary electrophoresis system simplifies protein analysis
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Subscribe To Our Newsletter & Stay Updated
